ABX Stock Analysis: Abacus Global Management | NYSE

Insurance - Life | NYSE, USA | Market Cap: 1.055m USD | 12M Return: 102.6% | Charts, Fundamentals & Technical Analysis

Asset Management, Life Settlements, Mortality Verification, Alternative Investments
Total Rating 53
Safety 53
Buy Signal 0.53
Insurance - Life
Industry Rotation: +1.7
Market Cap: 1.06B
Avg Turnover: 8.10M
Risk 3d forecast
Volatility63.7%
VaR 5th Pctl9.60%
VaR vs Median-6.54%
Reward TTM
Sharpe Ratio1.52
Rel. Str. IBD90.3
Rel. Str. Peer Group95
Character TTM
Beta0.518
Beta Downside0.039
Hurst Exponent0.537
Drawdowns 3y
Max DD62.79%
CAGR/Max DD0.34
CAGR/Mean DD0.78
EPS (Earnings per Share) EPS (Earnings per Share) of ABX over the last years for every Quarter: "2021-06": 0.25, "2021-09": 0.2496, "2021-12": 0.25, "2022-03": 0.03, "2022-06": 0.22, "2022-09": -0.26, "2022-12": -0.1388, "2023-03": -0.14, "2023-06": 0.1336, "2023-09": 0.0143, "2023-12": -0.0984, "2024-03": -0.0214, "2024-06": 0.18, "2024-09": 0.2, "2024-12": -0.22, "2025-03": 0.18, "2025-06": 0.22, "2025-09": 0.2, "2025-12": 0.23, "2026-03": 0.2,
Last SUE: -0.06
Qual. Beats: 0
Revenue Revenue of ABX over the last years for every Quarter: 2021-06: 0.33738, 2021-09: 0.321822, 2021-12: 0.321822, 2022-03: 0.203404, 2022-06: 5.691916, 2022-09: 11.507748, 2022-12: -4.580585, 2023-03: 10.273389, 2023-06: 11.378765, 2023-09: 21.12093, 2023-12: 23.695547, 2024-03: 21.487184, 2024-06: 29.076102, 2024-09: 28.148491, 2024-12: 33.212009, 2025-03: 44.139346, 2025-06: 56.22462, 2025-09: 62.975156, 2025-12: 71.898514, 2026-03: 59.390288,
Rev. CAGR: 108.74%
Rev. Trend: 97.6%
Qual. Beats: 0

Warnings

Choppy

Tailwinds

Rs Leader
Idiosyncratic Leader
Confidence

Seasonality 5.8 years of data

Jan +0.0% 9
Feb +0.0% 9
Mar +0.1% 9
Apr +0.1% 24
May -2.5% 46
Jun -2.7% 29
Jul +4.1% 22
Aug +19.4% 23
Sep -1.9% 11
Oct -8.7% 47
Nov +0.3% 23
Dec +0.4% 10

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: ABX Abacus Global Management

Abacus Global Management, Inc. (NYSE: ABX) is a U.S.-based alternative asset manager and market maker that operates across three business segments: Asset Management, Life Solutions, and Technology Services. Founded in 2004 and headquartered in Orlando, Florida, the company distributes its offerings through financial advisors, direct-to-consumer channels, and traditional life settlements intermediaries, with operations in the United States, Luxembourg, and other international markets. The firm rebranded from Abacus Life, Inc. to its current name in February 2025 to reflect its broader alternative asset management focus beyond its original life insurance roots.

The Life Solutions segment is the companys core business, acting as an intermediary that connects buyers and sellers in the life settlements market, where existing life insurance policies are sold by original owners to third-party investors. The Asset Management segment manages investments in alternative investment vehicles and exchange-traded funds on behalf of clients, while the Technology Services segment provides contract-based solutions such as real-time mortality verification and missing participant verification, which are specialized back-office services used by insurers, pension funds, and other participants in the life insurance market.

ABX is classified within the Financials sector under the Insurance Brokers sub-industry and trades as a small-cap stock with a market capitalization around $927 million. Its three-segment structure-combining origination of life insurance policy settlements, asset management, and related technology infrastructure-positions it as a vertically integrated participant in the alternative investments and life insurance services space.

Headlines to Watch Out For
  • Life settlement origination volume expands across operating segments
  • Interest rate shifts impact policy valuation and investment yields
  • Asset Management AUM growth drives recurring fee revenue
Piotroski VR-10 (Strict) 4.0
Net Income: 39.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.15 > 0.02 and ΔFCF/TA 47.11 > 1.0
NWC/Revenue: -28.43% < 20% (prev -51.52%; Δ 23.09% < -1%)
CFO/TA 0.15 > 3% & CFO 127.6m > Net Income 39.2m
Net Debt (316.4m) to EBITDA (113.5m): 2.79 < 3
Current Ratio: 0.52 > 1.5 & < 3
Outstanding Shares: last quarter (99.5m) vs 12m ago 2.10% < -2%
Gross Margin: 70.80% > 18% (prev 88.29%; Δ -17.49% > 0.5%)
Asset Turnover: 29.71% > 50% (prev 15.71%; Δ 14.00% > 0%)
Interest Coverage Ratio: 2.41 > 6 (EBIT TTM 95.7m / Interest Expense TTM 39.6m)
Altman Z'' 1.15
A: -0.09 (Total Current Assets 77.4m - Total Current Liabilities 148.6m) / Total Assets 829.8m
B: -0.04 (Retained Earnings -34.5m / Total Assets 829.8m)
C: 0.11 (EBIT TTM 95.7m / Avg Total Assets 843.2m)
D: 1.04 (Book Value of Equity 422.6m / Total Liabilities 407.2m)
Altman-Z'' = 1.15 = BB
Beneish M -1.93
DSRI: 1.34 (Receivables 40.2m/16.1m, Revenue 250.5m/134.6m)
GMI: 1.25 (GM 88.29% / 70.80%)
AQI: 0.97 (AQ_t 0.89 / AQ_t-1 0.92)
SGI: 1.86 (Revenue 250.5m / 134.6m)
TATA: -0.11 (NI 39.2m - CFO 127.6m) / TA 829.8m)
Beneish M = -1.93 (Cap -4..+1) = B
What is the price of ABX shares?

As of July 21, 2026, the stock is trading at USD 10.26 with a total of 458,637 shares traded. Over the past week, the price has changed by -6.73%, over one month by +7.32%, over three months by +6.43% and over the past year by +102.59%.

Current recommended Stop Loss: 9.60 (which is 6.4% or 1.2 ATR below the current price).

Is ABX a buy, sell or hold?

Abacus Global Management has no consensus analysts rating.

Abacus Global Management (ABX) - Fundamental Data Overview as of 15 July 2026
Market Cap USD = 1.06b (1.06b USD * 1.0 USD.USD)
P/E Trailing = 28.9474
P/E Forward = 10.5708
P/S = 4.2124
P/B = 2.5519
Revenue TTM = 250.5m USD
EBIT TTM = 95.7m USD
EBITDA TTM = 113.5m USD
Long Term Debt = 328.5m USD (from longTermDebt, last quarter)
Short Term Debt = 2.83m USD (from shortTermDebt, last quarter)
Debt = 353.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 11.3m
Net Debt = 316.4m USD (calculated: Debt 353.6m - CCE 37.2m)
Enterprise Value = 1.37b USD (1.06b + Debt 353.6m - CCE 37.2m)
Interest Coverage Ratio = 2.41 (Ebit TTM 95.7m / Interest Expense TTM 39.6m)
EV/FCF = 10.88x (Enterprise Value 1.37b / FCF TTM 126.0m)
FCF Yield = 9.19% (FCF TTM 126.0m / Enterprise Value 1.37b)
FCF Margin = 50.31% (FCF TTM 126.0m / Revenue TTM 250.5m)
Net Margin = 15.63% (Net Income TTM 39.2m / Revenue TTM 250.5m)
Gross Margin = 70.80% ((Revenue TTM 250.5m - Cost of Revenue TTM 73.1m) / Revenue TTM)
Gross Margin QoQ = 76.13% (prev 37.06%)
Tobins Q-Ratio = 1.65 (Enterprise Value 1.37b / Total Assets 829.8m)
Interest Expense / Debt = 11.21% (Interest Expense 39.6m / Debt 353.6m)
Taxrate = 30.12% (16.9m / 56.1m)
NOPAT = 66.9m (EBIT 95.7m * (1 - 30.12%))
Current Ratio = 0.52 (Total Current Assets 77.4m / Total Current Liabilities 148.6m)
Debt / Equity = 0.84 (Debt 353.6m / totalStockholderEquity, last quarter 422.6m)
Debt / EBITDA = 2.79 (Net Debt 316.4m / EBITDA 113.5m)
Debt / FCF = 2.51 (Net Debt 316.4m / FCF TTM 126.0m)
Total Stockholder Equity = 425.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.64% (Net Income 39.2m / Total Assets 829.8m)
RoE = 9.20% (Net Income TTM 39.2m / Total Stockholder Equity 425.6m)
RoCE = 12.69% (EBIT 95.7m / Capital Employed (Equity 425.6m + L.T.Debt 328.5m))
RoIC = 8.18% (NOPAT 66.9m / Invested Capital 817.3m)
WACC = 7.81% (E(1.06b)/V(1.41b) * Re(7.80%) + D(353.6m)/V(1.41b) * Rd(11.21%) * (1-Tc(0.30)))
Discount Rate = 7.80% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.86 | Cagr: 24.87%
[DCF] Terminal Value 75.44% ; FCFF base≈126.0m ; Y1≈126.5m ; Y5≈134.0m
[DCF] Fair Price = 18.44 (EV 2.08b - Net Debt 316.4m = Equity 1.77b / Shares 95.9m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.06 | # QB: 0
Revenue Correlation: 97.65 | Revenue CAGR: 108.7% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.24 | Chg30d=+0.00% | Revisions=+29% | Analysts=6
EPS next Quarter (2026-09-30): EPS=0.27 | Chg30d=+0.00% | Revisions=+62% | Analysts=5
EPS current Year (2026-12-31): EPS=1.01 | Chg30d=+0.00% | Revisions=+62% | GrowthEPS=+17.9% | GrowthRev=+16.3%
EPS next Year (2027-12-31): EPS=1.14 | Chg30d=+0.00% | Revisions=+50% | GrowthEPS=+12.0% | GrowthRev=+19.1%
[Analyst] Revisions Ratio: +75% (up=16, down=1)